Publications by authors named "John Flaherty"

Claim this Profile
E
Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.
Grace Lai-Hung Wong, Edward Gane, Calvin Q Pan, Scott Fung, Mang M Ma, John F Flaherty

Aliment Pharmacol Ther· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of tenofovir alafenamide in preventing hepatitis B virus recurrence after liver transplantation in patients with chronic kidney disease maintained on tenofovir disoproxil fumarate: Results from a phase 2 randomized trial.
Edward J Gane, Rica Dagooc, Dominic Ray-Chaudhuri, Vithika Suri, Frida Abramov, John F Flaherty

Am J Transplant· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to tenofovir alafenamide in virally-suppressed chronic hepatitis B patients with renal/hepatic impairment: Phase 2 study sub-analysis from Taiwan.
Chun-Jen Liu, Young-Suk Lim, Chi-Yi Chen, Chien-Hung Chen, Yi-Hsiang Huang, John F Flaherty

J Formos Med Assoc· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48.
Tarik Asselah, Pietro Lampertico, Soo Aleman, Marc Bourlière, Adrian Streinu-Cercel, John F Flaherty

Liver Int· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic hepatitis B virus infection increases the risk of kidney disease while antiviral therapy for hepatitis B virus can decrease kidney disease risk.
Kaori L Ito, Yuqing Zhang, Biao Li, Andrew King, Leland J Yee, John F Flaherty

BMC Nephrol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 Randomised Study of Bulevirtide as Monotherapy or Combined With Peg-IFNα-2a as Treatment for Chronic Hepatitis Delta.
Pietro Lampertico, Pavel O Bogomolov, Vladimir Chulanov, Tatiana Stepanova, Viacheslav Morozov, John F Flaherty

Liver Int· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide.
Maria Buti, Heiner Wedemeyer, Soo Aleman, Vladimir Chulanov, Viacheslav Morozov, John F Flaherty

J Hepatol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials.
Maria Buti, Young-Suk Lim, Henry Lik Yuen Chan, Kosh Agarwal, Patrick Marcellin, John F Flaherty

Aliment Pharmacol Ther· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial.
Heiner Wedemeyer, Soo Aleman, Maurizia Brunetto, Antje Blank, Pietro Andreone, John F Flaherty

J Hepatol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study.
Harry L A Janssen, Young-Suk Lim, Pietro Lampertico, Jeong Heo, Chi-Yi Chen, John F Flaherty

Lancet Gastroenterol Hepatol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blocking viral entry with bulevirtide reduces the number of HDV-infected hepatocytes in human liver biopsies.
Lena Allweiss, Annika Volmari, Vithika Suri, Jeffrey J Wallin, John F Flaherty

J Hepatol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B Patients.
Jinlin Hou, Qin Ning, Zhongping Duan, Yu Chen, Qing Xie, John Flaherty

J Clin Transl Hepatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world safety and effectiveness of tenofovir alafenamide for 144 weeks in Japanese patients with chronic hepatitis B.
Shuhei Hige, Kouji Aoki, Daisuke Nakamoto, John F Flaherty, Irina Botros

J Viral Hepat· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety.
Henry L Y Chan, Maria Buti, Young-Suk Lim, Kosh Agarwal, Patrick Marcellin, John F Flaherty

Am J Gastroenterol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks.
Scott K Fung, Calvin Q Pan, Grace Lai-Hung Wong, Wai-Kay Seto, Sang Hoon Ahn, John F Flaherty

Aliment Pharmacol Ther· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nutritional needs, resources, and barriers among unhoused adults cared for by a street medicine organization in Chicago, Illinois: a cross-sectional study.
Elizabeth J Adams, Michelle Lu, Richard Duan, Alyssa K Chao, Helen C Kessler, John P Flaherty

BMC Public Health· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
Young-Suk Lim, Henry L Y Chan, Sang Hoon Ahn, Wai Kay Seto, Qin Ning, John F Flaherty

JHEP Rep· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
Julius Hollnberger, Yang Liu, Simin Xu, Silvia Chang, Ross Martin, John Flaherty

J Hepatol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.
Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, Antje Blank, Pietro Andreone, John Flaherty

N Engl J Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B.
Young-Suk Lim, W Ray Kim, Douglas Dieterich, Jia-Horng Kao, John F Flaherty

Viruses· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of hepatocellular carcinoma in treatment-naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States.
W Ray Kim, Laura E Telep, Belinda Jump, Mei Lu, Heribert Ramroth, John Flaherty

Aliment Pharmacol Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide-a review of current data.
Young-Suk Lim, Wai-Kay Seto, Masayuki Kurosaki, Scott Fung, Jia-Horng Kao, John F Flaherty

Aliment Pharmacol Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV.
Calvin Q Pan, Ting-Tsung Chang, Si Hyun Bae, Maurizia Brunetto, Wai-Kay Seto, John F Flaherty

PLoS One· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case of flexor tenosynovitis caused by .
Kushali Patel, John Flaherty

BMJ Case Rep· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-year Treatment of Tenofovir Alafenamide . Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China.
Jinlin Hou, Qin Ning, Zhongping Duan, You Chen, Qing Xie, John F Flaherty

J Clin Transl Hepatol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis